{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atazanavir%2FRitonavir&page=5", "query": { "intervention": "Atazanavir/Ritonavir", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atazanavir%2FRitonavir&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atazanavir%2FRitonavir&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T13:02:26.596Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00042289", "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "atazanavir/cobicistat", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "elvitegravir/cobicistat", "type": "DRUG" }, { "name": "dolutegravir", "type": "DRUG" }, { "name": "tenofovir alafenamide fumarate (TAF)", "type": "DRUG" }, { "name": "TAF w/cobicistat", "type": "DRUG" }, { "name": "TAF w/cobicistat or ritonavir", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" }, { "name": "darunavir/cobicistat", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "atazanavir/ritonavir/tenofovir dosage #1", "type": "DRUG" }, { "name": "rifampicin", "type": "DRUG" }, { "name": "ethambutol", "type": "DRUG" }, { "name": "isoniazid", "type": "DRUG" }, { "name": "pyrazinamide", "type": "DRUG" }, { "name": "kanamycin", "type": "DRUG" }, { "name": "amikacin", "type": "DRUG" }, { "name": "capreomycin", "type": "DRUG" }, { "name": "moxifloxacin", "type": "DRUG" }, { "name": "levoflaxacin", "type": "DRUG" }, { "name": "ofloxacin", "type": "DRUG" }, { "name": "ethionamide/prothionamide", "type": "DRUG" }, { "name": "terizidone/cycloserine", "type": "DRUG" }, { "name": "para-aminosalicylic acid (PAS)", "type": "DRUG" }, { "name": "high dose INH", "type": "DRUG" }, { "name": "bedaquiline", "type": "DRUG" }, { "name": "clofazamine", "type": "DRUG" }, { "name": "delamanid", "type": "DRUG" }, { "name": "linezolid", "type": "DRUG" }, { "name": "pretomanid", "type": "DRUG" }, { "name": "ethinyl estradiol", "type": "DRUG" }, { "name": "etonogestrel implant", "type": "DRUG" }, { "name": "nevirapine", "type": "DRUG" }, { "name": "amprenavir", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "fosamprenavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "didanosine delayed release (Videx® EC)", "type": "DRUG" }, { "name": "emtricitabine", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "nelfinavir dosage #1", "type": "DRUG" }, { "name": "tipranavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #4", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "etravirine", "type": "DRUG" }, { "name": "maraviroc", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "tenofovir/atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "nelfinavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "rilpivirine", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1578, "start_date": "2003-06-09", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 39, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042289" }, { "nct_id": "NCT01106586", "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild Placebo", "type": "DRUG" }, { "name": "ATV Placebo", "type": "DRUG" }, { "name": "RTV Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 708, "start_date": "2010-04", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 86, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Denver", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106586" }, { "nct_id": "NCT01394133", "title": "Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infected" ], "interventions": [ { "name": "Tenofovir, Emtricitabine, Atazanavir, Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "21 Years to 40 Years · Female only" }, "enrollment_count": 0, "start_date": "2011-07", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-04-30", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01394133" }, { "nct_id": "NCT00084019", "title": "Atazanavir/Ritonavir Maintenance Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2004-07", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 11, "location_summary": "Palo Alto, California • Aurora, Colorado • Honolulu, Hawaii + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084019" }, { "nct_id": "NCT01467479", "title": "A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "BIOLOGICAL" }, { "name": "Highly Active Antiretroviral Therapy (HAART)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 185, "start_date": "2011-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467479" }, { "nct_id": "NCT00413153", "title": "Metabolic Effects of Switching Kaletra to Boosted Reyataz", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "atazanavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2006-05", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2010-03-09", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413153" }, { "nct_id": "NCT02603107", "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV/co", "type": "DRUG" }, { "name": "DRV/co", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-11-20", "completion_date": "2019-12-23", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 63, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603107" }, { "nct_id": "NCT01479361", "title": "Antiretroviral Drug Interaction Study in Volunteers With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "PCP", "Toxoplasmosis" ], "interventions": [ { "name": "Atovaquone 750 mg twice daily", "type": "DRUG" }, { "name": "Atovaquone 1500 mg twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2011-10-31", "completion_date": "2014-02-20", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479361" }, { "nct_id": "NCT00884793", "title": "Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" }, { "name": "Study NNRTI", "type": "DRUG" }, { "name": "Study PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2008-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-07-23", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00884793" }, { "nct_id": "NCT01003990", "title": "Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Atazanavir/Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 710, "start_date": "2002-10", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-05-11", "last_synced_at": "2026-10-14T13:02:26.596Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01003990" } ] }